6.13
Schlusskurs vom Vortag:
$6.64
Offen:
$6.61
24-Stunden-Volumen:
1.14M
Relative Volume:
1.12
Marktkapitalisierung:
$105.14M
Einnahmen:
$13.11M
Nettoeinkommen (Verlust:
$-124.02M
KGV:
-0.4298
EPS:
-14.261
Netto-Cashflow:
$-107.25M
1W Leistung:
-18.81%
1M Leistung:
-47.74%
6M Leistung:
-54.08%
1J Leistung:
-69.37%
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
TNXP
Tonix Pharmaceuticals Holding Corp
|
6.13 | 105.14M | 13.11M | -124.02M | -107.25M | -14.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
|
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-06-25 | Eingeleitet | Raymond James | Strong Buy |
| 2026-05-04 | Eingeleitet | TD Cowen | Buy |
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals Q3 2026 Earnings Date and Estimates - MarketBeat
Tonix Pharmaceuticals Gains On Update for TNX-102 SL - Baystreet.ca
Tonix Pharmaceuticals Holding (NasdaqGS:TNXP) Stock Forecast & Analyst Predictions - Simply Wall Street
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Rating Raised to "Hold" at Wall Street Zen - MarketBeat
Tonix Pharmaceuticals (TNXP) 10K Form and Latest SEC Filings 2026 - MarketBeat
Why Is Tonix Pharmaceuticals (NASDAQ:TNXP) Moving Into Focus? - Kalkine Media
Tonix Pharmaceuticals Holding (TNXP) Stock Price, News & Analysis - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to Sell - MarketBeat
Tonix Pharmaceuticals (TNXP) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Tonix expands Medicare coverage for fibromyalgia drug TONMYA - Investing.com
Tonix Pharmaceuticals Adds ~21M Medicare Lives for TONMYA, Total Coverage Now ~166M U.S. Lives - TradingView
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA® - Yahoo Finance
Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement for TONMYA® - GlobeNewswire
Raymond James reiterates Strong Buy on Tonix Pharma stock at $27 - Investing.com
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears - marketbeat.com
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears - MarketBeat
Tonix Pharmaceuticals Targets TONMYA Growth as Lyme Prevention Trial Nears - Yahoo Finance
Could Market Volatility Test Tonix Pharmaceuticals (NASDAQ:TNXP)? - Kalkine Media
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push By Investing.com - Investing.com Canada
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push By Investing.com - Investing.com India
Tonix Pharmaceuticals at Cantor conference: launch gains and pipeline push By Investing.com - Investing.com UK
Q3 EPS Estimate for Tonix Pharmaceuticals Raised by Analyst - marketbeat.com
What macro factors could move Tonix Pharmaceuticals (NASDAQ:TNXP) shares this week? - Kalkine Media
Tonix Pharma Appoints New Chief Commercial Officer - The Globe and Mail
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Passes Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer - Minichart
Tonix Pharmaceuticals Promotes Thomas Englese to Chief Commercial Officer - citybiz
TNXP Looks 393.2% Overvalued on GF Value™ - GuruFocus
Tonix Pharmaceuticals Holding Corp. Announces Appointment of Thomas Englese to Chief Commercial Officer, Effective September 8, 2026 - marketscreener.com
Why is Tonix Pharmaceuticals (NASDAQ:TNXP) stock in focus as Wall Street reopens today? - Kalkine Media
Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer - Yahoo Finance
Price-Driven Insight from (TNXP) for Rule-Based Strategy - Stock Traders Daily
TNXP: $11.0 Million in Tonmya® Net Revenue in 2Q26 - finance.yahoo.com
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference - GlobeNewswire
Tonix Pharmaceuticals to Participate in Cantor’s 2026 Global Healthcare Conference - Yahoo Finance
Tonix CEO will speak at a healthcare conference Sept. 10 - Stock Titan
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com India
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Buys $27,580.00 in Stock - MarketBeat
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock - Investing.com
Tonix Pharmaceuticals CEO Seth Lederman buys $27,580 in stock By Investing.com - Investing.com UK
Tonix Pharma (NASDAQ: TNXP) CEO adds 2,000 shares in IRA - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Increased to Hold at Wall Street Zen - marketbeat.com
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Canada
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com Nigeria
Tonix Pharmaceuticals director bagger buys $12,600 in stock By Investing.com - Investing.com UK
Tonix Pharmaceuticals director bagger buys $12,600 in stock - investing.com
Tonix Pharmaceuticals (TNXP) director buys 1,000 company shares - Stock Titan
Tonix (TNXP) Market: Adds 1.29% to Close at $12.55; the Near-Term Reference Band Stretches From $11.92 to $13.18 in the Latest ReadingPositive Gamma - siam.in
Tonix Pharma Names CEO Seth Lederman Interim CMO - The Globe and Mail
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tonix Pharmaceuticals Holding Corp-Aktie (TNXP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BAGGER RICHARD H | Director |
Aug 20 '26 |
Buy |
12.60 |
1,000 |
12,600 |
1,000 |
| Taylor Carolyn E. | Director |
Jun 12 '26 |
Buy |
10.55 |
1,415 |
14,928 |
1,833 |
| LEDERMAN SETH | Chief Executive Officer |
Jun 09 '26 |
Buy |
11.79 |
5,000 |
58,950 |
9,005 |
| Stillwell Richard Newcomb | Director |
Jun 08 '26 |
Buy |
11.65 |
5,000 |
58,250 |
5,000 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 31 '26 |
Buy |
12.62 |
5,000 |
63,100 |
20,001 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 18 '26 |
Buy |
14.89 |
15,000 |
223,350 |
15,001 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):